Skip Navigation LinksHome   |   Reference Center   |   Publication List   |   PublicationDetail
  • Print
  • Share

Bone Marrow Transplant 52(1):59-65, 2017

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.

Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S

PMID: 27427921

PubMed Central
PMCID: PMC5215562
Manuscript: | Abstract | Full Text | PDF

CIBMTR Study #        SC14-02

Last Updated: 6/5/2015 10:00 AM